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Abstract 
 
Cutaneous melanoma has become a growing health problem in the United States, 
affecting all age groups, ethnic groups, including both genders. The incidence rate of 
melanoma is rising faster than any other malignancy, with the American Cancer Society 
projecting nearly 60,000 new cases and over 8,000 deaths due to melanoma for the year 
2007.  One of the main components of diagnosis and management of cutaneous 
melanoma is staging of the patient.  Given that the metastasis status of the lymph nodes is 
of great prognostic significance for melanoma, a new minimally invasive procedure 
called sentinel lymph node biopsy has become the preferred method of care for patients 
diagnosed with melanoma.  However, to date, there has been no cumulative research 
looking at the evidence of sentinel lymph node biopsies in terms of overall survival and 
disease free survival.  In addition, the theory that sentinel lymph node biopsies might 
increase the risk of in-transit metastases has been postulated.   A systematic review was 
done evaluating the role of the routine use of sentinel lymph node biopsy in staging of 
melanoma to see if there is an overall benefit to patients diagnosed with melanoma in 
performing SLN biopsies.  
The results of the comprehensive search revealed that there is fair evidence that 
the use of SLN biopsy in patients diagnosed with Stage I or II melanoma does not 
increase the risk of in-transit metastases compared to either WLE only, ELND, or 
delayed lymph node dissection of patients with clinically palpable nodes.  Furthermore,  
the results in this paper demonstrates fair evidence that SLN provides a significantly 
better disease free survival but perhaps not an overall survival benefit.   Given that there 
is no good treatment for advanced stage melanoma and sentinel lymph node biopsies do 
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not provide an overall longer survival, the decision to undergo a sentinel lymph node 
biopsy should be one of shared decision making.   
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Introduction 
 
Burden of Disease: 
 
 Cutaneous melanoma has become a growing health problem in the United States, 
affecting all age groups, ethnic groups, including both genders.  Melanoma is a type of 
cancer that arises from specific cells in the skin called melanocytes. Malignant melanoma 
develops in these cells when melanocytes stop responding to normal cellular growth 
control mechanisms and become capable of local invasion or spreading to other organs. 
The incidence rate of cutaneous melanoma is on the rise, with the American Cancer 
Society projecting nearly 60,000 new cases and over 8,000 deaths due to melanoma for 
the year 2007.
1
  The incidence rate of melanoma is rising faster than any other 
malignancy.  Incidence rates between 1973 and 2002 have risen in all age groups, as well 
as in both men and women.  Incidence rates in men between the ages of 55 and 64 years 
have increased four-fold, and five-fold for men 65 years and older.
2 
 The incidence of 
melanoma is lower among Hispanics and African Americans compared to whites, but 
rates are increasing among this population as well.  Based on rates from 2003-2005, 
according to the data from the Surveillance, Epidemiology, and End Results (SEER) 
program of the National Cancer Institute, one in fifty-five men and women will be 
diagnosed with melanoma over their lifetime. The life-time risk of developing invasive 
melanoma is 3.15% for whites and 0.11% for African Americans.
3
  Cutaneous melanoma 
is the sixth most common cancer in the United States, is the most common cancer in 
young women aged 25-29 years, and is second only to breast in women aged 30-34 
years.
4
  The median age at diagnosis is 57 years, affecting a younger patient population 
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than most solid tumors.  Thus, cutaneous melanoma has become an increasingly common 
form of cancer.  
 The mortality rate from melanoma in men and women increased from 1975-1990, 
but since 1990 there has been no change in mortality among men and a decrease in 
mortality among women.  The age-adjusted mortality rate for cutaneous melanoma from 
2000-2004 was 2.6% per 100,000 men and women per year. In specific age groups, the 
highest mortality rate is seen in the age group 75 to 84, with 23.1% of men and women 
dying from melanoma.
3
  The relative survival rates for melanoma are fairly good, 
compared to other malignancies.  The five-year relative survival rate has increased since 
1975 for all ages, races, and gender. Based on data from 1996-2003, the overall 5-year 
relative survival was 91.1%.
3
   Although the relative survival rate for primary cutaneous 
melanoma is fairly good, it still represents a huge burden of disease among people in the 
United States, as well as around the world.  
 The rising incidence of melanoma also represents a huge economic burden to the 
healthcare system.  One model found that the cost of diagnosing and treating new cases 
of invasive melanoma in 1997 was $560 million. Of the total cost, stage  I and stage II 
were 5.5% of the total cost (%31 million); stage III was 34% ($191 million); stage IV 
was 55% ($309 million).
5
  This is most likely a large underestimate of the true economic 
impact of melanoma on society given this analysis did not include the cost of screening, 
the cost of biopsies of suspect lesions, the cost of diagnosing and treating melanoma in 
situ, the cost of continued surveillance, and indirect costs, such as loss of income and 
employment.  
 6 
 Screening, diagnosis, management and treatment of melanoma varies 
considerably among healthcare providers.  While some melanoma care is delivered via 
local physicians in community-based strategies, others are delivered via a 
multidisciplinary based approach.  The Michigan Multidisciplinary Melanoma Clinic 
(MDMC) found that patients treated within the MDMC compared to patients treated 
within other sites in the Michigan community would save a third party payer roughly 
$1600 per patient, with equivalent rates of surgical morbidity, length of hospitalization, 
and long-term survival.
6
 However, many patients are not treated in a multi-disciplinary 
based environment, and the costs of melanoma healthcare is high. If the incidence of 
melanoma continues to increase annually, the estimation of cost for melanoma treatment 
by Medicare may exceed $5 billion by the year 2010.
7
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Staging 
 Both environmental and genetic factors contribute to the development of 
malignant melanoma.  The main environmental factor is sun exposure.   There are clinical 
signs and symptoms that increase suspicions of possible melanoma.  The ABCDE 
criterion for gross inspection of the skin is an acronym used by physicians and other 
health care professionals to aid in the early recognition of potential cutaneous malignant 
melanomas.  Inspecting suspicious nevi lesions for asymmetry, border irregularity, color 
variegation, greater than 6 mm diameter, and evolving lesions over time for changes in 
size, shape, symptom, surface, and shades of color, aid in screening and diagnosis of 
malignant melanoma.
8
  
Despite these clinical signs, the only way to accurately diagnose melanoma is by 
skin biopsy.  After biopsy confirms melanoma, the next step is staging the patient.
4
  In 
2002, the American Joint Committee on Cancer published its 6
th
 edition of the T,N,M 
melanoma staging system.  Given that staging is associated with prognosis and treatment, 
it is critical to establish if there is local, regional, or distant metastasis at the time of 
diagnosis. The T classification is based on Breslow thickness (mm) and histologic 
evidence of ulceration, two of the most important prognostic indictors of the primary 
tumor.
4
  However, Breslow thickness, measured from the top of the granular level of the 
epidermis to the deepest point of tumor penetration, is the best indicator of outcome.
7
 The 
Clark level of invasion, or the level of depth penetration from the epidermis to the 
subcutaneous fat, is significant only for thin lesions (1.0mm or less). 
9, 10 
 The N 
classification describes the extent of lymph node disease. N is based on the number of 
regional nodes with disease and the tumor burden in the nodes, either macroscopic or 
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microscopic. Macroscopic disease in the lymph nodes is clinically palpable disease or 
disease found by clinical imaging studies and verified by histology.  Microscopic disease 
is disease that is not found clinically via physical exam or on imaging studies, but is 
detected only on histologic evaluation.  Metastasis to a regional lymph node is the most 
important prognostic factor in early-stage melanoma. The final staging classification is 
M, which is based on the anatomic location of distant metastases and the level of serum 
lactate dehydrogenase.
4
  Given that the strongest predictor of melanoma survival is the 
status of regional lymph nodes and up to one-fifth of patients diagnosed with a cutaneous 
melanoma will develop metastatic disease, revealing the status of the lymph nodes 
provides vital information for patient counseling, management, and treatment of 
cutaneous melanoma.
10
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History of Staging of Cutaneous Melanoma  
Cutaneous melanoma commonly metastasizes to regional lymph nodes, with the 
regional nodal basin usually being the first site of metastasis.  Before the acceptance of 
sentinel lymph node biopsy (SLN) as a staging mechanism, either elective lymph node 
dissection (ELND) or delayed lymphadenectomy with clinical palpable nodes was 
performed on patients with melanoma.
9
 ELND has been the routine management of 
melanoma for the past twenty-five years because it was a way to stage the nodal basin.  
The major downside was that the majority of patients did not have metastatic disease. 
These patients had to go through the unnecessary procedure, suffering considerable 
morbidity and complications, without any therapeutic benefit.  With these invasive 
procedures came many complications, such as lymphedema, nerve damage, and acute 
wound problems.
9
  In addition, randomized control trials comparing ELND with delayed 
lymph node dissection at the time of clinical recurrence showed no significant overall 
survival benefit in patients undergoing ELND. 
11
 
Improvements in the management of cutaneous melanoma began in 1977 when 
Fee et al published their results on the role of lymphoscintigraphy in determining the 
lymphatic drainage patterns from a primary cutaneous melanoma.
12
 In 1990, Dr. Donald 
Morton began working on studies using lymphoscintigraphy to identify the drainage 
patterns of truncal melanoma and then used mapping techniques to identify the SLN with 
a minimally invasive procedure.  Morton believed that the primary tumor will first drain 
to one or more of the sentinel lymph nodes in the regional lymph node basin.  Thus, 
because the sentinel lymph node is the first drainage site for tumor metastasis, the tumor 
status of the SLN can be used to predict the tumor status of the other lymph nodes in the 
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basin.  In addition, he found that the status of the SLN reflected the status of the entire 
regional lymph nodal basin, with a low false-negative rate.
13
  Many studies have 
confirmed that the success rate of sentinel lymph node biopsy procedure is very high, 
around 98%. 
14-17
  With the advent of sentinel lymph node biopsies, there have been 
several studies showing that the status of the sentinel lymph node is the most important 
prognostic factor of survival.
18, 19
  Studies show roughly 88.5% of patients with a 
negative SLN biopsy are free of disease at three years with an overall survival rate of 
93%, compared with 55.8% of patients with a positive SLN biopsy who have a 67% 
overall survival rate. 
18, 20
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Sentinel Lymph Node Biopsy 
   The SLN biopsy is a procedure in which the sentinel lymph node is identified 
and removed; usually it is the first lymph node in the pathway from the primary tumor to 
the nodal basin.  If the SLN is positive for tumor cells via histopathologic testing, other 
nodes in the basin are probably affected and need to be treated with a complete 
lymphadenectomy.  If the node is negative, it is likely that the other nodes in the basin 
will not be positive and no further surgical intervention is warranted.
9
  There are three 
methods used in the sentinel lymph node biopsy procedure: a preoperative 
lymphoscintigram, a blue-dye injection at the primary melanoma site immediately pre-
operatively, and finally a intraoperative use of a gamma probe. 
21
  The intraoperative 
hand held gamma probe is beneficial because it allows for an easier search for the SLN 
resulting in a smaller incision site and shorter operating time, as well as ensuring a more 
complete removal of the SLN.
14
  Using data from the Sunbelt Melanoma Trial, 
McMasters et al found the detection of sentinel nodes is best achieved by removing all 
nodes that stain blue and all nodes that show radioactivity greater than 10% of the count 
in the hottest node. 
22, 23
   
 SLN biopsy is a less invasive procedure than ELND, but still has risks. For 
example, potential complications include excessive bleeding at the site of biopsy, pain or 
numbness at the site of biopsy, infection, lymphedema, nerve damage at the site of 
biopsy, and anaphylaxis in 1% of patients from the blue dye used during the procedure.
24
 
Many studies have shown that the complication rate from SLN procedures is lower than 
for complete lymph node dissection, with complication rates around 5%. 
25, 26
 Since the 
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only way to reliably stage and gather prognostic information is to see if the regional 
lymph nodes have disease, the SLN biopsy procedure has rapidly gained acceptance.
10
  
Even though the rate for minor complications following SLN biopsy is small, 
there is a concern that the SLN biopsy procedure might increase the risk of in-transit 
metastases (ITM) by entrapment of tumor cells in the dermal lymphatic vessels during 
the procedure.
27
  ITM’s are subcutaneous metastases located between the site of the 
primary cutaneous melanoma and the regional lymph node basin. These represent a 
serious clinical problem as they are difficult to manage and very hard to eradicate. 
28
  A 
literature review of all studies calculating local/ITM recurrence as an outcome following 
SLN procedure by Thomas and Clark showed that the overall recurrence rate was 9.0%. 
They concluded that patients who had the SLN biopsy had double the incidence of 
local/ITM recurrence compared to patients treated solely with wide local excision; and 
patients who had the SLN biopsy followed by selective lymphadenectomy had four times 
the incidence of local/ITM recurrence compared to patients treated solely with wide local 
excision.
29
   However, this review only looked at ITM recurrence in patients who had 
sentinel lymph node biopsies, not studies directly comparing the recurrence to other 
staging procedures.  Thus, there remains a concern for an increased risk of ITM 
recurrence following SNL biopsy.   
Even though lymphatic mapping with sentinel lymph node biopsy has become the 
procedure of choice for staging cutaneous melanomas of intermediate thickness, the 
procedure is underutilized.  Between 1998 and 2000, Baxter and Tuttle, using 
Surveillance, Epidemiology, and End Results (SEER) data,  found that 47% of patients 
with a melanoma of > 1.00 mm thick underwent lymphatic mapping and SLN biopsy.
30
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Similar results were found by Stitzenberg et al where only 48% of patients with 
intermediate thickness melanomas underwent lymphatic mapping and sentinel 
lymphadenectomy in North Carolina.
31
  Thus, even though sentinel lymph node biopsy 
has become the preferred method for management of melanoma, its use is far from being 
widespread.  
Although there is agreement that sentinel lymph node biopsy can reveal the status 
of the lymph node and has become the preferred method for staging melanomas by the 
National Comprehensive Cancer Network treatment guidelines
32
, it is not clear whether 
the routine use of sentinel lymph node biopsies for diagnosed cutaneous melanomas leads 
to improved health outcomes, such as fewer recurrences, fewer surgeries and overall 
improved survival.    A systematic review was done evaluating the role of the routine use 
of sentinel lymph node biopsy in staging of melanoma to see if there is an overall benefit 
to patients diagnosed with melanoma in performing SLN biopsies.   
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Methods 
 
 
 
Search Strategy: 
To identify relevant studies of the outcome of sentinel lymph node biopsies in 
staging of cutaneous melanoma, a MEDLINE database search using the MeSH terms 
“melanoma,” “sentinel lymph node biopsy,” “lymph nodes” and “biopsy” was completed.  
Since the introduction of sentinel lymph node biopsy was introduced in the early 90’s by 
Dr. Morton, dates were limited from 1990 to present.  Sentinel lymph node biopsy did not 
become a MeSH term until 2001 so the MeSH terms “lymph node” and “biopsy” had to 
be used to identify all relevant articles prior to 2001.  Articles were limited to English and 
Humans.  A MEDLINE search using the terms “melanoma” and “sentinel lymph node 
biopsy” as keywords with limits on studies being added to Medline in the last 180 days 
was also completed. The Cochrane database library was also searched using the search 
term “melanoma”.  References of all relevant papers found in the searches were 
reviewed, as well as review articles, which found an additional two studies.    
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Inclusion Criteria: 
Randomized control trials, case-control trials, and observational and retrospective 
reviews that compared sentinel lymph node biopsies to either another form of staging of 
the regional lymph nodes or no dissection for staging in patients with primary cutaneous 
melanoma were included.. All types of trials were included, regardless of the number of 
participants or study duration.  All patients with a diagnosis of primary cutaneous 
melanoma with no evidence of metastases at distant sites, regardless of their breslow 
thickness were also included.  Trials that included only patients with melanoma of the 
head and neck were excluded. Trials whose patients were children or adolescents were 
also excluded.  
 
 
 
Figure 1: Study search and selection process: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Potentially relevant citations identified 
 after liberal screening of the search on medline 
(n=1044) 
Citations excluded with reasons prior to abstract 
review  
(n=386) 
Studies retrieved for more detailed evaluation after 
abstract 
(n=63) 
Studies excluded (after evaluation of full text) 
from systematic review with reasons 
(n=45) Relevant studies included in systematic review 
n=18 
5 for ITM, 14 for survival 
Studies not from medline 
n=2  
1 for ITM, 1 for survival 
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Data Extraction 
 
Only one investigator independently extracted the data from relevant articles onto 
a standardized data collection form that included the following information: year of 
publication, inclusion and exclusion criteria, number of patients randomized or number of 
patients in study, number of patients lost to follow-up, staging procedure of melanoma, 
number of recurrences, survival, and mortality. The randomized control trials, articles 
were graded via quality grading of good, fair, or poor via the predefined criteria 
developed by the USPSTF and the National Health Service Centre for Reviews and 
Dissemination. For all other studies, quality was based on selection of cases or cohorts 
and controls, adjustment for confounders, methods of outcome assessment, length of 
follow-up and statistical analysis.  
 
 
 
 
Results 
 
Figure 1 illustrates the results of the study search and selection process of the 
included articles.  Six articles were identified: one observation
33
, four retrospective 
reviews
34-37
 and one randomized control trial
38
, addressing the risk of in-transit 
metastases following sentinel lymph node biopsies compared to other methods of staging, 
such as wide local excision (WLE) , elective lymphadenectomy (ELND) or delayed 
lymphadenectomy (DLND).  Four studies compared either the overall ITM or ITM as a 
first recurrence rate in patients who had a WLE followed by a positive SLN biopsy to 
patients who had delayed lymph node dissection secondary to clinically palpable lymph 
node metastases.
33, 35, 36,38
  Two studies compared overall ITM and ITM as a first 
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recurrence in patients who had either WLE only, WLE plus SLN biopsy or elective 
lymph node dissection.
34, 37
 
Fifteen studies were identified, only one of which was a randomized control trial, 
that addressed survival of patients undergoing SLN biopsy compared to WLE only, 
DLND, and/or ELND.  The majority of the studies were retrospective database reviews.  
The majority of the studies included patients who were either stage I and/or stage II. 
There was one study that included patients who were stage III
39
 and one study that 
included patients who had thin melanomas with a breslow thickness of 0.76-1mm only.
40
   
The studies reported on different outcome measures of survival, including overall 
survival
39-49
, disease free/recurrence free surviva,l
38-40, 43-45, 48, 50, 51
 and melanoma specific 
survival
38, 40, 51
 by creation of Kaplan-Meier survival curves.  There was one study that 
calculated the relative risk of melanoma related death.
52
  Five of the studies compared 
SLN biopsy to ELND
41-43, 50, 51
; six studies compared SLN biopsy to delayed lymph node 
dissection
38, 39, 46-49
; and four studies compared SLN biopsy to observation. 
40, 44, 45, 52
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Does SLN biopsy increase the risk of in-transit metastases? 
  
 The six articles that addressed the rate of in-transit metastases are displayed in 
Table 1. 
33-38
  One of these studies was observation, one was a randomized control trial 
and the rest were done by retrospective data review from various melanoma databases. 
Only one study showed that the overall rate of ITM recurrence during the study period 
was statistically higher for patients who received a positive SLN followed by a complete 
lymphadenectomy compared to patients with clinically palpable nodes receiving a 
delayed lymph node dissection.
33
  Another study showed a statistically significant higher 
rate of ITM as a first recurrence in patients receiving a SLN biopsy followed by CLND 
compared to patients with clinically palpable nodes receiving a DLND, but a non-
significant higher rate of overall ITM recurrence rate.
35
  Of the two studies looking at 
WLE, WLE + SLN biopsies, and ELND, only one study showed a statistically significant 
higher rate of ITM as a first recurrence in SLN compared with ELND
34
, but both studies 
showed no significant difference in the overall ITM recurrence rate.
34, 37
     The 
randomized control trial showed a non-significant overall rate of ITM recurrence of 
observation plus DLND compared to SLN.
38
 
 Given that all but two of the studies were retrospective, there is inherent selection 
bias and confounding to these studies.  There was no randomization of groups so there 
will always be some confounding factors present that cannot be controlled for, even with 
statistical analysis.  Some of the studies gave inclusion and exclusion criteria to 
determine which cases should be included, but none of the studies gave detail as to how 
many reviewers went through the database, as having multiple reviewers would ensure all 
correct cases were used.  Also, there is no mention as to blinding of the people who 
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abstracted the outcomes from the cases. Bias would be limited if an independent reviewer 
measuring outcome was blinded to which surgical procedure the patient obtained.   
 Even though there was only one study that showed a significant higher rate of 
overall ITM recurrence during five years in patients with a positive SLN biopsy followed 
by a CLND (23% vs 8%, p=0.027), the overall quality of the study was poor.
33
 This study 
suffered significantly from selection bias, confounding, and measurement bias.  The 
observational study failed to reveal how the patients were selected to be included in the 
study. They stated they excluded patients with melanoma of the head and neck, and 
included patients who were Stage I and II.  Also, there was no mention of patients who 
were potentially lost to follow-up.  There was no mention of the procedure protocol for 
SLN biopsy, of the success rate of the SLN procedure, of how they assessed the histology 
of the lymph node biopsies, and if the same surgeon performed all surgical procedures.  
The two groups were statistically different at baseline with respect to breslow thickness 
and ulceration status of the primary lesion.  Although the group who underwent SLN 
biopsy plus CLND had a deeper Breslow thickness as well as a greater percentage of 
ulcerations, logistic regression analysis did not show that Breslow thickness, age, sex, 
tumor location, tumor histology, or ulceration status had any statistically significant 
prognostic value. They found that the rate of ITM recurrence was increased in patients 
undergoing SLN biopsy + CLND compared to patients who underwent a delayed lymph 
node dissection.  However, the patients who had SLN biopsy + CLND had more 
advanced disease at baseline with a poorer survival rate.  This study is generalizable to 
patients who have clinically diagnosed Stage I or Stage II cutaneous melanoma, 
excluding melanomas of the head and neck. 
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 Kretschmer et al found a statistically significant increased rate of ITM as a first 
recurrence in patients with a positive SLN biopsy compared to patients with clinically 
palpable nodes with DLND (27.3% vs 17.6%, p=0.03, and a 22.4% recurrence rate 
among + SLN plus CLND), but a non-significant overall ITM 5 year recurrence rate 
between the two groups, 33.75% and 33.3%, respectively.
35
  In addition, this study also 
looked at overall and recurrence free survival of the types of nodal surgery, but failed to 
give significance values.  Thus this study was not included in the analysis of the second 
question. The 5-year overall survival rate and the 5 year disease free survival rate for 
positive SLN was 54.4% and 38.6%, respectively, and 37.4% and 11.6% respectively for 
DLND.   After controlling for several prognostic factors (breslow thickness, epidermal 
ulceration, age, location of primary lesion, gender), they noted that there was no 
significant difference in risk of developing ITM for the time of node dissection (SLN 
biopsy vs DLND).   Overall, selection bias was not as strong in this study because the 
study gave specific inclusion and exclusion criteria. Patients with Stage I melanoma, 
patients with neck lymph node excision, patients with clinically palpable nodes, and 
patients with unknown primary tumors were excluded.  In addition, at baseline, the 
groups were similar in regards to potential prognostic factors, such as site of primary 
tumor, breslow thickness, ulceration, and sex. The follow-up rate was complete for 
97.8% of the patients, and the ten patients that were lost to follow-up all had negative 
SLN biopsies. Given that the study outlined their operative procedure and how they 
performed the SLN biopsy procedure (standard three method protocol), identified their 
definition of a sentinel node, and stated that they performed CLND and DLND according 
to established surgical protocol, measurement bias was kept to a minimum. Even though 
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they did not state their success rate of the SLN procedure, they did state that one surgeon 
performed 80% of all surgeries.  Even though the authors assessed the two groups for 
initial comparability in regards to many prognostic factors, there is the potential for other 
confounders that they did not control for introducing bias.  
 This study is also generalizable to patients diagnosed with Stage I or II cutaneous 
melanoma, excluding those with palpable lymph nodes or neck lymph node dissections. 
They found that the median interval between primary tumor excision and palpable nodal 
metastases was 12 months in the DLND group whereas the median time interval to the 
occurrence of a first distant or nodal recurrence was 47.5 months in the positive SLN 
group. Thus, the time during which ITM may manifest as a first recurrence is almost four 
times longer if nodal recurrences are avoided by using the SLN biopsy procedure.  Given 
that the overall ITM reoccurrence rate was not different between the groups, they 
concluded that sentinel lymph node biopsy does not increase the risk of  ITM.  
 The final study that compared ITM recurrence of positive SLN plus CLND with 
DLND in patients with clinically palpable nodes showed no significant difference in ITM 
as a first recurrence (20.1% vs 17.0%, no p value reported). 
36
  However, they found a 
significant lower rate of ITM recurrence in patients who received DLND compared to 
SLN plus CLND when only comparing patients who relapsed (25.9% vs 37.3%, p=0.02).  
The difference in the median time to ITM recurrence was not significant in the CLND 
group (231 days) vs. the DLND group (240 days).  Given that the study specified 
inclusion and exclusion criteria for the cases they chose form the database, selection bias 
was minimized.  However, the two groups were different in regards to the location of the 
primary site and the DLND group had a higher number of lymph node(s) with 
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metastases. The bias from measurement was reduced by having the Pathology department 
confirm measurement of both Clark level and Breslow thickness. Also, the SLN biopsy 
procedure was according to standard protocol and the false-negative rate of the procedure 
was 4.9%, similar to other studies.  They also defined ITM and excluded patients from 
the DLND group who already had ITM, which limits measurement bias.  Although they 
used statistical analysis to find which prognostic factors influenced the rate of ITM in the 
entire SLN group, they did not use statistical analysis to control for potential confounders 
between the SLN group and the DLND group, which were different at baseline.  
Furthermore, the results of this study are only applicable to patient with melanoma with a 
breslow thickness ≥ 0.75mm or Clarks level ≥ IV.  Given that there was no significant 
difference in overall survival using Kaplan Meier graphs between DLND and CLND in 
patients who developed ITM and there was no difference in rate of ITM as a first 
reoccurrence in the groups, the authors concluded that the SNL biopsy procedure does 
not increase the risk of ITM.  Furthermore, the estimated overall 3 year survival (from the 
date of relapse) in ITM patients was better when compared to other types of relapses after 
CLND and DLND.  
 Two studies compared WLE only, WLE plus SLN biopsy or ELND.  Kang et al 
found a significantly higher rate of ITM as a first recurrence in patients undergoing 
ELND, without controlling for potential confounders, but no difference in overall ITM 
recurrence.
34
  In their study they found the overall incidence of ITM increased with depth 
of primary lesion, and thus matched patients within the study by T stage. In the 1,875 
patients who were matched (625 in each group) for T stage, they found no significant 
difference in overall ITM or ITM as a first recurrence for WLE, SLND, or ELND.  They 
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also controlled for confounding by matching patients from each treatment group by age, 
sex, breslow depth, and primary site location. Again, from the analysis of 1,680 patients 
(560 in each group) they found no significant difference in ITM overall or as a first 
recurrence in the treatment groups.  From their Kaplan-Meier survival curves, there was 
no significant treatment-related differences in rate of ITM as a first recurrence, however, 
patients with WLE and SLND did better with respect to overall ITM than the ELND 
group. With matching of patients for T stage and again for potential confounders, there 
was no statistical difference between the two groups on Kaplan Meier curves.  
Given that this study used matching of potential prognostic factors, confounding 
was minimized, but not eliminated.  Selection bias was high because the study did not 
state specific inclusion or exclusion criteria. There was also incomplete data for the 
patients on ulceration status of primary lesion, with 45.9% melanoma of unknown 
ulceration. This is of great significance because ulceration status is a prognostic factor for 
melanoma.  Since almost half of the ulceration status of the melanomas was unknown, 
this prognostic factor could not be controlled for in statistical analysis. The three groups 
were not comparable at baseline, with the SLN biopsy group having the highest 
percentage of patients over 50 years of age and the ELND group having a greater 
percentage of melanomas with a breslow thickness > 2mm (no mention of significance). 
In addition, the SLN biopsy and ELND group had more patients with a higher Clarks 
level. From the beginning, the patients in the ELND group had a poorer prognosis, with 
higher breslow thickness and Clark’s level.  However, the authors did control for thee 
potential confounders in matched pair statistical analysis.  The authors defined their 
outcome of interest, ITM, but they did not give any details on operative procedures, 
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histology of the SLN, or success rate of the SLN procedure, leading to potential 
measurement bias.  This study is only generalizable to patients with a stage I or II 
cutaneous melanoma, since this was the only inclusion criteria for the study. In 
conclusion, the authors state that there is not an increased incidence of ITM after SLN 
biops vs WLE or ELND and there is no survival disadvantage, either disease free or 
overall, in those SLND patients who did develop ITM.  
 The final study by Van Poll et al also showed no significant difference in ITM as 
a first recurrence between patients in WLE, SLND, and ELND upon univariate 
analysis.
37
  Even after multivariate analysis adjusting for Breslow thickness, ulceration, 
age, sex, and follow-up time there was no difference in ITM recurrence.  When 
comparing nodal disease in the groups, univariate analysis showed that tumor negative 
SLN group had a significantly lower rate of ITM  as a first recurrence (1.7% vs 4.5%, 
p=0.03)  and overall ITM (2.5% vs 5.5% p=0.04) than tumor negative ELND.  However, 
for tumor positive disease there was no significant difference. The authors performed 
another subgroup analysis in patients with evidence of regional metastatic disease, a 
group with WLE followed by a delayed lymph node dissection of clinically palpable 
metastatic nodes to a group with WLE with SLN biopsy followed by a completion lymph 
node dissection within 3 to 4 weeks. From this analysis, the total ITM rate was 
significantly lower in the SLN with CLND compared to DLND (10.8% vs 24.3% 
p=0.008).  Although the authors minimized selection bias by stating inclusion and 
exclusion criteria prior to database review, the groups were not initially comparable. The 
WLE group had a higher proportion of men and the patients were older at age of 
diagnosis.  The breslow thickness and ulceration rates were higher in the WLE plus 
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ELND group. The authors stated that the treatment for all three groups used the same 
surgical protocols over the 10 year study period and defined their outcome measurement 
definitions of local, in-transit, regional, and distant melanoma recurrences. Even though 
the groups had varying prognostic factors as baseline, the authors did control for many 
potential confounders (age, sex, tumor thickness, ulceration status, Clark’s level, primary 
tumor site location, and follow-up period) via multivariate analysis and multiple 
regression. This study is generalizable to patients diagnosed with cutaneous melanoma 
with a breslow thickness >1mm.  The group of patients who received immediate regional 
lymph node dissection because of a positive SLN biopsy had a lower incidence of ITM 
compared to patients treated with WLE followed by delayed lymph node dissection at 
time of clinically palpable lymph node metastases. Thus, the authors concluded that their 
results did not support the hypothesis that mechanical entrapment of tumor cells in 
lymphatic channels due to surgical interference with the regional nodes causes ITM.  The  
risk of developing ITM was not increased by SLN biopsy or ELND.  
 In conclusion, from the results of these trials, there seems to be fair evidence that 
the use of SLN biopsy in patients diagnosed with Stage I or II melanoma does not 
increase the risk of in-transit metastases compared to either WLE only, ELND, or 
delayed lymph node dissection of patients with clinically palpable nodes.  
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Is the survival in favor of patients undergoing SLN biopsy? 
 
The fifteen articles that address survival in patients who underwent sentinel 
lymph node biopsy are displayed in Table 2.  The majority of the articles found were 
retrospective database reviews comparing SLN biopsy patients to either ELND, DLND, 
or WLE and observation only.  Given the limitations and bias inherent to retrospective 
database reviews, there is not strong evidence to make a valid conclusion on SLN 
biopsies and overall survival and disease free survival from the studies analyzed in this 
review.  There was one randomized control trial
38
 that looked at the primary outcome of 
overall survival. This RCT was only given a quality rating of fair as well due to bias in its 
internal validity.   
Five retrospective database review articles were identified comparing SLN 
biopsies to ELND
41-43, 50, 51
.  Three of these studies reported overall survival (OS) as their 
primary endpoint
41-43
 and two studies reported disease free or recurrence free survival 
(DFS/RFS) as their endpoints
50, 51
.  The study by Essner et al found no significant 
difference in OS at five years when comparing all patients who received a SLN  CLND 
compared to patients receiving an ELND, nor was there a significant OS when comparing 
only node positive SLN patients + CLND to node positive patients who received 
ELND
43
.  This analysis was after a matched-pair analysis on age, gender, location of 
primary lesion and breslow thickness. However, the analysis failed to control for 
ulceration status, Clarks level, and type of histological melanoma, all of which affect 
prognosis.  
The study by Doubrovsky
42
 also found no significant OS in patients treated with 
SLN biopsy  CLND vs ELND at five years. Furthermore, when this study used 
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multivariate analysis, the type of operation (SLN vs ELND) had no significant affect on 
patient survival (p=0.24).  In this study, the two groups were different from baseline, with 
the SLN group being older, but having fewer ulcerative lesions and not as high of a 
breslow thickness. However, the study performed by Dessureault et al found a significant 
OS difference in patients treated with SLN vs ELND vs observation alone (p<0.0001) at 
five years.  However, this study was rated as poor, as data was collected from 12 
institutions with no standardization of diagnosis, staging, or treatment techniques and 
there was a difference in follow-up time. In addition, there was no baseline comparison of 
the groups and no statistical analysis controlling for potential confounders. From the 
results of these three trials, it seems that there is poor to fair evidence resulting from 
retrospective reviews that performing SLN biopsies results in no difference in overall 
survival compared to ELND. 
From the two studies looking at DFS/RFS, Tsutsumida
50
 found no significant 
DFS at 3 years in patients treated with SLN vs ELND, or in patients who had a positive 
SLN biopsy vs patients who had a positive ELND result.  Clary et al 
51
 also found no 
difference in DFS at 3 years when comparing SLN patients to ELND.  However, Clary et 
al performed a subgroup analysis on all high risk patients, defined as patients who had 
breslow thickness > 3.0mm, the presence of nodal metastases and age >50.  In analyzing 
all of the patients who were at high risk, the RFS for breslow thickness > 3.0 mm and for 
age > 50 years was significantly better for ELND patients compared to SLN patients at 3 
years.  For node negative high risk patients, the RFS was also significantly better for 
ELND patients compared to SLN patients.  These results point towards a disadvantage of 
performing SLN biopsies. However, these results are from a retrospective designed study 
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with several limitations, such as short follow-up period and its design.   From the five 
studies comparing ELND to SLN biopsy, it seems there is no difference in OS or DFS. 
Although, it seems that there might be a negative risk by decreasing DFS in node 
negative patients by performing SLN biopsy.   
The literature search identified four studies comparing SLN biopsy to 
observation.  Three of these studies, all retrospective, reported OS and one of the studies, 
an observational cohort, reported relative risk.  The studies by Gutzmer et al
44
, Koskivuo 
et al
45
, and Starz et al
40
, found no significant OS difference in patients treated with SLN 
biopsy vs observation.  However, in a subgroup analysis performed by Kosviuo of 
patients with a positive SLN compared to observation, there was a significant difference 
in OS, with more patients benefiting from observation. These studies also point towards 
SLN biopsies offering a significantly better DFS compared to observation (see table 2).  
The study performed by Mohrle et al
52
 found that the relative risk of melanoma related 
death to be 0.8, but was not statistically significant, comparing patients who had 
undergone SLN to observation.  The relative risk did not change when comparing 
patients who had positive or negative SLN biopsies to observation.  In conclusion, these 
overall fair quality articles point towards no difference in OS for performing SLN 
biopsies, but perhaps point towards an advantage for regional control in improving DFS.   
The literature review revealed six articles comparing SLN biopsy to DLND when 
clinically palpable nodes were present.  Given that SLN biopsy has replaced ELND in the 
management of melanoma, comparing SLN biopsy to DLND is more imperative.  All six 
of these studies reported OS as an endpoint
38, 39, 46-49
.   Rutkowski et al
39
 found that there 
was no difference in OS or DFS at 5 years, when calculated from the date of primary 
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tumor excision, for patients treated with positive SLN biopsy plus CLND compared to 
DLND. However, they found a significant OS difference favoring SLN biopsy plus 
CLND when calculated from the time of lymphadenectomy (48% vs 38%, p=0.02).  This 
article does not support an improved OS, or even a DFS, in patients who are stage III and 
have clinical disease in lymph nodes undergoing SLN biopsy plus CLND compared to 
DLND.  Van Akkooi et al also found that there was no significant difference in OS at 5 
years, when calculated from date of primary tumor excision, for patients treated with 
SLN biopsy plus CLND vs. DLND
49
.  Even when patients with nodes containing 
submicrometastases were excluded from analysis, there was still no difference in OS.  
The authors are in agreement with Rutkowski et al and conclude there is no survival 
benefit in performing SLN biopsies.  The main bias in the both of these studiess is that 
the two study groups were different at baseline, and they do not factor differences during 
their statistical analysis for OS survival. 
On the other hand, Kretschmer et al found a significant 13% OS difference at 5 
years, calculated from time of primary tumor excision, in patients treated with positive 
SLN biopsy plus CLND compared to DLND.  This study represented cases from five 
different clinical centers, with one of the centers not performing DLND. One of the main 
bias with this study is that the data came from 5 different centers.  There was no way of 
making sure everyone was treated the same, and thus the measurements were most likely 
not equal, valid, and reliable given that many different surgeons performed the 
procedures.  Another bias in this study is that ulceration status was not available for all 
patients because three sites did not measure ulceration status. Since ulceration status is a 
prognostic factor in melanoma, this introduces confounding. In Morton et al’s 
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retrospective review, a matched pair analysis was performed on 287 patients, matched for 
pT stage, ulceration, sex, age, and total number of tumor-involved nodes, using a 
computer program.  This analysis revealed 5, 10, and 15 year significant OS, calculated 
from time of primary tumor excision, in favor of positive SLN biopsy plus CLND 
compared to DLND.  The authors conclude that the result from this study indicate that 
melanoma behaves according to the incubator hypothesis, where melanoma metastasis 
first to lymph nodes where it remains latent before metastasizing further (as opposed to 
the marker hypothesis, where melanoma metastases via lymphatics and blood 
simultaneously.  Thus, finding tumors cells in the SLN is merely a marker that the 
melanoma has already metastasized and removal of tumor in the lymph nodes is unlikely 
to have a therapeutic effect) Thus, there is a clinical window where the tumor can be 
removed before it spreads. The authors calculated the proportion of patients who would 
benefit from an early lymphadenectomy based on the matched pair analysis (if these 
patients represented the entire population of patients with melanoma). They calculated 
7.4% of patients would benefit from early lymphadenectomy.   
Finally, the study by Starz et al compared SLN biopsy  CLND to DLND in 
melanoma patients with breslow thickness greater than 0.75mm
48
.  For all patients who 
had undergone SLN compared to DLND, there was a significant OS difference favoring 
SLN biopsy.  When comparing only patients who had positive SLN biopsy plus CLND 
compared to positive DLND, there was barely a significant difference in OS favoring 
SLN plus CLND (p=0.0419). Differences in follow-up times were not taken into 
consideration in calculating the OS time, which leads to measurement bias.  A subgroup 
analysis was performed on patients with intermediate thickness (0.76mm-4mm) and OS 
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was significantly better in the SLN biopsy group compared to DLND (p=0.0076).  The 
authors conclude that early removal of lymph nodes is beneficial in the management of 
melanoma.   
In summary, there are two retrospective reviews which show no overall survival 
benefit for performing SLN biopsies and three retrospective studies showing a potential 
overall survival benefit in performing SLN biopsies.  Given that these are retrospective 
reviews, they suffer from confounding, selection bias, and measurement bias.  Many of 
the studies do not control for all potential confounders, such as age, differences in length 
of follow-up time, histology, breslow thickness, site of primary lesion, and ulceration 
status.  Given that many of the studies do not contain equal comparison groups, it would 
be important to control for differences, although some studies do not.  Many suffer from 
selection bias because they do not state guidelines as to how patients were selected. Many 
also are subject to measurement bias because some do not explain techniques of 
performing SLN biopsies or the SLN success rate.  Thus, many authors conclude in their 
studies that a randomized control trial is needed to answer the question of an overall 
survival benefit. 
Only one of the fifteen articles was a randomized control trial by Morton et al.
38
  
This multi-center trial included patients from the United States, Australia, and Europe, 
which randomized patients to either 1) wide local excision and SLN biopsy with 
immediate lymphadenectomy if patients had a positive SLN biopsy or to 2) wide local 
excision and observation with lymphadenectomy if patient had clinically palpable lymph 
nodes.  The third interim results of this trial are reported in the paper.  Patients who 
received SLN biopsy had a significantly better disease free survival at 5 years compared 
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to patients who had observation only (78.31.6% vs 73.12.1% 95%CI of 0.59-0.93, 
p=0,009).  The subgroup analysis comparing patients who had a positive SLN biopsy 
with CLND to patients with WLE and DLND also showed a significantly better five year 
survival rate for patients who received the SLN biopsy (72.34.6% and 52.45.9%, 95% 
CI of 0.32-0.81, p=0.004).   There was no significant difference in overall survival 
between the two groups at the 3
rd
 interim analysis.  Perhaps one of the reasons that the 
SLN group showed no difference in overall survival was because they had more distant 
recurrences compared to the observation group. At the 4
th
 of the 5
th
 planned interim 
analysis, melanoma specific survival is now significant (HR 0.74, p < 0.001) and the 
DFS remains significant (HR 0.74, p < 0.001).  This is the first RCT to look at SLN vs 
DLND. At the 3
rd
 interim analysis there was significant difference in DFS, but not OS. In 
the 4
th
 interim analysis there seems to be a significant difference in OS as well.  
Even though this was a well-designed RCT, the study suffered from several bias’ 
and resulted in a overall quality grading of fair.  The main problem with the RCT by 
Morton was their analysis of the post-hoc subgroup survival benefit. When they did this 
subgroup analysis, the randomization of patient characteristics for the two groups was 
lost, thus confounding and selection bias were introduced. Another potential bias is they 
did not include patients with false-negative results in the group who underwent 
lymphadenectomy.  Another problem with this study is that they only present the results 
on a subgroup of patients with melanomas 1.2-3.5mm, but fail to report the overall 
results.   
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Discussion 
 Sentinel lymph node biopsy was adopted as the preferred method of care in the 
United States by the World Health Organization and by National Comprehensive Cancer 
Network treatment guidelines
32
.  The reason is because studies show patients who have a 
negative sentinel lymph node biopsy have a better prognosis compared to patients who 
have a positive sentinel lymph node.  Thus, SLN biopsy offers a minimally invasive 
staging procedure resulting in a prognostic indictor. Due to the morbidity and lack of 
overall survival advantage of elective lymph node dissection, sentinel lymph node 
biopsies replaced ELND as a staging procedure and became the preferred method even 
though there were no studies showing a therapeutic advantage of SLN biopsy.   
 One of the main concerns raised about SLN biopsy procedure was the fear that 
SLN biopsy increases the risk of in-transit metastasis by mechanically disrupting the flow 
of lymph to the regional nodes. If SLN biopsy did increase the risk of ITM, the procedure 
would essentially eliminate or reduce any survival or therapeutic advantages because 
ITM confer a poor prognosis with a worse 5 year survival rate of 25% and are more 
difficult to manage. 
28
 However, from the analysis of the articles identified from my 
comprehensive search, there is fair evidence pointing towards the use of SLN biopsy in 
patients diagnosed with Stage I or II melanoma does not increase the risk of in-transit 
metastases compared to either WLE only, ELND, or delayed lymph node dissection of 
patients with clinically palpable nodes. There is little evidence from these studies that 
early nodal removal by SLN biopsy has any impact on the natural history of ITM.  The 
fear of increased risk of  ITM with SLN biopsy was one of the main arguments against 
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the widespread use of SLN.  From my review, it seems that ITM should not be a concern 
of mechanical disruption but perhaps of the biology of ITM.   
 Another question raised with the implementation of SLN biopsies was if the 
procedure resulted in a subsequent increase in disease free survival and overall survival. 
From the fifteen articles found during this comprehensive literature search, SLN provides 
a significantly better disease free survival but perhaps not an overall survival benefit. 
There were three retrospective reviews pointing towards an OS benefit in patients 
undergoing SLN biopsy compared to DLND, but two retrospective reviews that lacked to 
find this same benefit.  The one randomized control trial, considered to be the gold 
standard but only given a fair quality grade, showed a significant improvement in DFS 
and the newest results show an improvement in OS as well. However, this RCT only 
shows the results from a small subgroup of the entire patients included in the MSLT-1 
trial.  Biologically, it makes sense that patients undergoing SLN biopsies with subsequent 
complete lymphadenectomy would have a prolonged disease free survival period because 
the patient is given an early stage III diagnosis with detection and removal of metastasis 
in the lymph nodes.  However, strong evidence is lacking in the possibility that 
performing SLN biopsies results in an overall survival benefit. 
Perhaps one reason that studies have failed to show an overall survival for 
patients treated with SLN biopsy is because not all melanoma metastasis are present in 
the regional lymph nodes. In about 2/3
rd
 of cases of melanoma, metastatic disease 
develops as locoregional metastasis, and in 1/3
rd
 of cases it presents as distant metastasis. 
SLN biopsy will detect and remove only regional lymph node metastasis.  In one study, 
50% of patients developed metastasis not in the regional lymph nodes.  Distant metastasis 
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in this study appeared to be an early event in metastatic spread and could have occurred 
via hematogenous spread, resulting in support of the marker hypothesis.
53
  Thus, SLN 
biopsy might not show a significant improved overall survival in studies because 
hematogenous spread has already occurred in a majority of patients. Perhaps SLN biopsy 
will become only one part of the staging technique in the future where other modalities 
might be able  to identify metastasis that have bypassed the regional lymph nodes.  
Another possible reason the studies failed to show an improvement in overall 
survival with SLN biopsy is because it represents a lead-time bias.  The studies identified 
showed an improvement in disease free survival, but not of overall survival, except for 
the newest results of the 4
th
 interim analysis of the MSLT-1 Trial.  The SLN biopsy 
procedure is detecting melanoma metastases early in the asymptomatic period.  Thus, the 
patients who get a SLN biopsy procedure are being upstaged earlier than patients who 
have a delayed lymphadenectomy.  However, since the overall survival between the two 
groups is the same, the SLN biopsy patients are not actually living longer than the 
observation patients but are merely finding out about their disease at an earlier point.  
 One of the main hopes of the SLN biopsy was to identify patients who have 
positive sentinel lymph nodes so they could be treated further, either with completion 
lymphadenectomy and/or adjuvant therapy.   All patients with positive sentinel lymph 
nodes are additionally treated with a completion lymphadenectomy to remove any further 
possible metastasis. It is assumed that all positive sentinel nodes will go on to cause overt 
disease.  Thus, by performing a completion lymphadenectomy it will provide the patient 
with a survival advantage.  However, this might not be the case as some studies have 
suggested that not all positive sentinel lymph nodes will go on to cause overt nodal 
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disease if not removed early. Starz et al concluded that perhaps only deposits greater than 
1 mm (SIII) were of adverse prognostic significance. 
48
  In this study, patients’ S 
classification, or the maximum distance from the interior margin of the lymph node 
capsule, provided better prognostic information compared to the mere presence of a 
positive SLN, as patients with an SIII classification had a significantly worse overall 
survival rate.  Another study suggested that perhaps only micrometastases found by 
immunohistochemical analysis were not of prognostic significance.
54
 There is evidence 
that not all occult nodal disease will progress to overt clinical disease; some 
micrometastases in the SLN will either be destroyed by host-immune processes or 
become dormant.
55
 Thus, research is still being done to help shed light on prognostic 
factors to determine which patients would be better suited for the SLN biopsy procedure.   
Approximately 15-20% of patients with a positive SLN are found to have 
additional disease with CLND
56
, which means 80% of patients with a positive SLN do 
not require this procedure. In addition, the CLND procedure is more invasive than a SLN 
procedure, causing complications in roughly 37.2% of patients in the MSLT-1 trial. In 
this trial, the procedures were performed by experienced surgeons, and thus most likely 
underestimate the true complication rate of CLND on patients who might not need 
CLND. 
57
 A multi-institutional study evaluated patients who were SLN positive but did 
not undergo a CLND compared to a contemporary series of melanoma patients who had 
CLND
56
.  They found the overall disease specific survival of patients with a positive SLN 
who did not undergo CLND was not significantly different from patients who had a 
positive SLN who underwent CLND.  Thus, the authors concluded obtaining a CLND 
after SLN made no difference on survival.  Given this study was retrospective review, 
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more studies need to be performed to definitely answer this question.    A recent 
retrospective study by Roka et al attempted to identify clinico-pathological features to 
predict which positive SLN patients will have additional disease present in CLND in 
hopes of identifying high-risk patients.
58
  They concluded that clinico-pathological 
features can not reliably be used to identify patients who will have additional disease on 
CLND, and thus all patients with a positive SLN biopsy require a CLND.  The 
therapeutic utility of CLND after a positive SLN is still largely unknown and is currently 
being tested in the Multicenter Selective Lymphadenectomy Trial (MSLT II) randomized 
control trial.  If there is a survival benefit for CLND after SLN biopsy, then it would 
favor performing SLN biopsies on all patients with melanoma.   
 Performing SLN biopsies on patients with melanoma is thought to improve 
patient care by identifying patients in which adjuvant treatment would be helpful. 
However, this would be the case only if adjuvant treatment existed for melanoma that 
increased overall survival and/or disease free survival.  A recent systematic review found 
no systematic adjuvant therapy (interferon, levamisole, vaccine or chemotherapy) that 
conferred a significant overall survival benefit in patients with high-risk primary 
melanoma.
59
  However, there was a significant improvement in disease-free survival 
(DFS) for patients treated with high-dose interferon
60
.  Even though DFS is improved 
with high-dose interferon, the medication also causes at least grade three toxic effects in 
most patients. Thus, the benefits of additional months of disease free survival, yet 
ultimately no effect on overall survival, have to be weighed against the year-long toxic 
effects of interferon therapy.  SLN biopsy would identify patients who have positive 
nodal disease status, but these patients may or may not benefit from adjuvant treatment.   
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If sentinel lymph node biopsy with completion lymphadenectomy does not confer 
any sort of survival advantage and there is no conclusive evidence that adjuvant treatment 
is beneficial, then why use this procedure on patients diagnosed with melanoma?  Given 
that SLN biopsy is minimally-invasive with minor side effects, some patients may wish 
to go through this procedure simply to know their lymph node status, and thus their 
prognostic status.  Patients may feel reassured knowing that if they have a negative 
sentinel lymph node, their survival will be better than if they are positive. Even though 
there is roughly a 4% failure rate and being sentinel lymph node negative is not a 100% 
guarantee for no recurrences (around 13% of SLN negative patients will develop 
recurrence by 3 years
18
), patients will still have a better idea of their long-term outcome.  
On the other hand, if a patient has a false-positive SLN, this information can be 
devastating and lead to unnecessary completion lymphadenectomy and/or adjuvant 
therapy.  
 In a questionnaire survey with patients who underwent SLN biopsy, 91% 
believed that they gained some benefit from the procedure, such as peace of mind or the 
ability to plan for the future, both of which were independent of the outcome of the 
biopsy.
61
  However, this benefit seemed to be only short-term. Regardless, the majority of 
patients approved of the procedure and would recommend it to others. One advantage of 
the SLN biopsy, even though there is still not universal agreement that it has a therapeutic 
advantage, is that it may provide patients with psychosocial benefits necessary to cope 
with the diagnosis of cutaneous melanoma.  
SLN biopsy is the only minimally invasive staging technique that is available for 
cutaneous melanoma. Several studies have looked at the use of CT, PET and  
99m
Tc-MIBI 
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scintigraphy as possible alternatives.  However, none of these modalities are as sensitive 
as SLN biopsy at detecting microscopic positive nodal metastasis.
62-65
  There has been 
further research on other screening alternatives. One study compared methallothioneines 
over-expression to SLN biopsy and found that it was comparable to SLN as a prognostic 
marker, but cheaper and easier.
66
   Other research has looked at the prognostic 
information of tumor-infiltrating lymphocytes
67
 and p-cadherin
68
. The information that 
SLN biopsy, a one time procedure, provides may be considered important to both the 
clinician and patient in terms of management options and psychosocial factors.  Yet there 
is still further research being done on other potential alternatives.    
The use of ultrasound with fine needle aspiration in management of cutaneous 
melanoma has shown potential promise for an additional role in melanoma management.   
Given that ultrasound has a lower sensitivity and high false negative rate, ultrasound 
cannot completely replace SLN biopsies. However, studies have shown using US with 
FNA allows 10%-16% of patients to be spared the SLN biopsy procedure. 
69, 70
    Another 
newly published study highlight the potential promise of use of inductively coupled 
plasma-mass spectrometry (ICP-MS) with FNA as a means of nonsurgical evaluation of 
sentinel lymph nodes.
71
  Perhaps by using US with FNA, the SLN biopsy procedure can 
be limited to only high risk patients, or even using a non-surgical alternative such as ICP-
MS, thus reducing the number of unnecessary SLN biopsies. 
Even though the SLN biopsy is the preferred method for the treatment of 
melanomas, widespread use of this procedure has not been obtained, with roughly one-
half of patients receiving this standard.
28-29
   A retrospective review of a cancer registry at 
a teaching hospital in Greenville, South Carolina, showed that only 60% of patients 
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diagnosed with melanoma received a SLN biopsy, and the non-universal adherence to 
standards did not appear to have an effect on overall survival, although the study was not 
powered to show this outcome. 
72
  Concerns have been raised that this procedure might 
not be feasible for management of all patients presenting with melanoma. Given that SLN 
is a multi-disciplinary approach, with the need for surgeons, pathologists, and nuclear 
medicine physicians, it is not surprising that the national standards have not been 
universally met.   
 Another potential barrier to wide-spread implementation of SLN biopsies is 
because of the learning curve of the procedure, with 20-30 cases needing to be performed 
prior to independent utilization to achieve success rates greater than 90%
73, 74
.  Thus, only 
experienced surgeons should be performing this technique. However, the SLN biopsy 
procedure is not limited to high volume specialty institutions as one study proved the 
feasibility of the SLN procedure in a community-based institution with comparable 
technical success rates and false-negatives rates.
75
  Another study compared performing 
SLN biopsy as an inpatient procedure to an outpatient day surgery and found that there 
were no significant differences in time between diagnosis and surgery, prolonged hospital 
stay and complication rates.
61
  The patients had a greater satisfaction with outpatient 
surgery and it reduces cost and use of hospital inpatient beds.  Regardless of the setting, 
the key to successful SLN procedure is quality control of the various multi-disciplines.  
Given that SLN biopsy is the preferred method, and it is feasible not only at high volume 
specialty clinics, more research looking at  the barriers to access of care for patients 
presenting with cutaneous melanoma should be pursued. 
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 In light that the evidence for SLN biopsy is one of clinical equipoise,  the cost-
effectiveness of this procedure must also be considered.  For melanomas less than 1 mm 
in thickness, there is much controversy over whether or not SLN biopsy should be 
performed, given only a very small percentage of patients would benefit from this 
procedure.  The SLN biopsy procedure costs $10,096 to $15,223, compared to $1,000 to 
$1,720 for wide local excision alone.   In one quantitative method analysis of cost-
effectiveness for performing SLN biopsies in patients with melanomas less than 1.2 mm 
in thickness found that a large number of SLN biopsies would need to be performed to 
identify one patient with regional disease. The estimated the cost per life saved ranged 
between $627,000 to $931,000 for melanomas less than 1.2mm and even greater for 
melanomas less than 1mm, up to $153,00 annual cost per life saved.  These authors 
conclude by raising the question as to whether or not it is cost-effective to perform SLN 
biopsies in this population group.  
76
   
Another study looked at the cost-effectiveness, including treatment, toxicity, 
follow-up and relapse cost,  using a decision analytical model comparing four treatment 
strategies in patients with Stage II melanoma (greater than 1 mm).  Their primary 
outcome was cost in US dollars per quality-adjusted relapse-free life year saved.  They 
found that using interferon treatment was more cost-effective than no treatment.  The 
most cost-effective was to perform SLN and treat only those with positive disease with 
high dose interferon at $18,700/QALY.
77
   Currently, it appears that it might not be cost-
effective to perform SLN on all melanomas less than 1mm. For melanomas greater than 1 
mm, the SLN biopsy might be cost-effective in determining which patients to treat with 
adjuvant interferon, although treatment with interferon remains controversial.   
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 Even if the SLN biopsy procedure does not drastically improve survival, it is a 
diagnostic procedure that allows for nodal staging of melanoma.  At this stage, it seems 
highly unlikely that the AJCC will revert back to clinical staging of nodal disease because 
the SLN biopsy procedure does provide better control of regional disease, thus improving 
disease free survival.  Wide local excision with delayed lymphadenectomy when a patient 
has clinically palpable disease is not the best option for management of regional nodal 
disease of cutaneous melanoma.  By the time the DLND is performed, extracapsular 
extension, invasion of neurovascular structures makes regional disease control more 
difficult than performing a SLN biopsy +/- complete lymphadenectomy.
78
  Thus, even 
though there is not widespread agreement that SLN improves overall survival, it does 
control local disease, providing patients with a significantly better chance of remaining 
disease free without recurrences.   SLN biopsy remains the best option currently 
available.   Perhaps with further research on other modalities, such as ultrasound and/or 
molecular markers, the use of SLN biopsy can be limited to only high-risk patients, thus 
minimizing unnecessary procedures.   
 SLN biopsy can identify the 15-20% of patients with melanoma that have 
clinically negative lymph nodes but occult regional nodal metastasis, thus who would 
might benefit from a lymphadenectomy. The majority of patients will undergo this 
procedure and not have negative SLN biopsies.  Many studies have recently been done 
attempting to create a model that incorporates the factors that are important in 
determining of the SLN is positive.
79-83
   The majority of the models studied looked at 
prognostic factors beyond breslow depth, such as mitotic rate, age, angiolymphatic 
invasion, regression and microsatellitosis. These models will allow for an improved 
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ability to predict the presence of SLN metastasis, which can help with individual patient 
risk estimation and decision making to help the patient make an informed decision on  if 
SLN is right for them.  One of these models was a nomogram that when tested against 
predictions based on the AJCC clinical staging system was found to be more accurate and 
discriminating. 
79
 Hopefully, models such as these can help reduce the number of SLN 
biopsies so that patients only at high risk for regional nodal mets will be subject to this 
minimally invasive procedure.   
 Given that all the important questions surrounding the use of SLN melanoma are 
still unanswered and data is currently being collected for the MSLT I and II  trials, I think 
it is important for physicians to have a discussion with their patients who are diagnosed 
with cutaneous melanoma.  I think it is important for the patient to know that the sentinel 
lymph node biopsy is stated as the preferred method of care by the AJCC and the WHO, 
but there are still questions that remain unanswered.  Patients need to be aware that SLN 
biopsy does not increase the risk of in-transit metastases. They also need to be aware that 
undergoing the SLN biopsy probably does not improve overall survival, as provided by 
the results of current studies.  The patient also needs to be aware of all the facts 
surrounding the procedure: the false-negative rate is around 10%; the false-positive rate is 
about 20%; there is a 10% minor complication rate with the procedure, but this increases 
to 40% with a completion lymphadecetomy, and not every patient with a positive SLN 
will have additional disease found with their completion lymphadecetomy; and it is 
controversial if the microscopic disease in the SLN will actually progress and cause 
clinically detectable disease; and finally, there are no adjuvant therapies that improve 
overall survival in patients with high-risk melanoma. Patients should be aware of the pros 
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and cons of each option, discuss them with their physician provider and family/friends, 
and make their own decision given that this is a preference-sensitive decision with 
clinical equipoise. Perhaps new research will shed light on the ability to identify high-risk 
melanoma patients who would be more likely to benefit from a SLN biopsy.  Until this 
research becomes available, shared decision making with the patient should be done 
surrounding this topic. 
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Table 1:  Studies measuring ITM recurrence as outcome 
Author, Year Study Design Intervention ITM as a first 
recurrence 
P value Overall ITM 
recurrence rate 
P 
value 
Quality 
Grading 
Estourgie, 
2004
33
 Observational 
61 + SLN + CLND 
-- -- 
23% 
0.027 poor 60 DLND + 
palpable nodes 
8% 
Kretschmer, 
2005
35
 
Retrospective
+ 
database review 
244 +SLN + CLND 27.3% 
0.03 
33.75% 
0.38 fair 
199 DLND + 
palpable nodes 
17.6% 33.3% 
Rutkowski, 
2006
36
 Retrospective 
database review 
963 SLN - 4.8% 
ns (not 
given) 
-- -- fair 
224 + SLN + CLND 20.1% 
DLND + palpable 
nodes 
17.0% 
Van Poll, 
2005
37
 Retrospective 
database review
£ 
1035 WLE 2.5% 
0.24 
4.9% 
0.27 fair 754 WLE + SLN 2.4% 3.6% 
229 WLE + ELND 4.4% 5.7% 
Kang, 2005
34
 
Retrospective
*
 
database review 
2,2271 WLE 1.59% 
0.0008 
3.36% 
0.2405 fair 
1,016 WLE + 
SLND 
1.67% 3.64% 
625 WLE + ELND 2.56% 6.56% 
Morton, 2006
38
 
RCT 
814 SLN  CLND 
-- -- 
7.7% 
0.38 good 
533 WLE  DLND 8.4% 
* Results show in the table are for unmatched analysis. Overall incidence and ITM as first recurrence rates for matched analysis are 
not shown in table.   
+ Results do not show the overall and ITM first recurrence rate for SLN negative biopsies 
£ Results do not show subgroup analysis.  
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Table 2: Studies measuring survival: overall survival (OS), disease free survival (DFS), recurrence free survival (RFS), 
melanoma specific survival (MSS) 
Note: ~ refers to my interpretation of the Kaplan Meier Curve if not stated in the study 
 
Author, 
Year 
Study 
Design 
AJCC 
stage 
Intervention Type of 
Survival 
Survival 
(%) 
P 
value 
Type of 
Survival  
Survival P 
value 
 Time 
period 
Quality  
Grading 
Essner, 
1999
43 
Retrospective 
Database 
review
 
Stage I 
267
*
 SLN  
CLND OS 
 
-- 
0.98 
 
DFS -- 0.25 
5 year
+ 
fair 
267
*
 ELND 
Node positive 
patients 
42+SLN/CLND 
OS -- 0.08
£
 
 
32 ELND 
Clary, 
2001
51
 
Retrospective 
Database 
review 
Stage 
I/II 
152 SLN 
RFS
 
71% 
0.12 MSS -- 0.87 
3 year 
 
fair 
329 ELND 80% 
All high risk 
patients 
SLN 
RFS for 
breslow > 
3mm 
~ 47% 
 
 
0.04 
 
RFS for 
age > 50 
years 
 
 
~ 65% 
 
 
0.01 
ELND ~ 75% ~ 82% 
node negative 
high risk
∫ 
90 SLN RFS 
~ 70% 
 
 
0.04 
 
167 ELND ~ 82% 
Dessureault, 
2001
41
 
Retrospective 
Database 
review 
Stage 
IB/IIA
€ 
 
5, 156 - observe 
OS 
69.8% 
< 
0.0001 
 5 year poor 2,032 - SLN 90.5% 
1,836 - ELND 77.7% 
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Doubrovsky, 
2004
42
 
Retrospective 
database 
review 
> 1.5-
mm 
thick 
672 SLN  
CLND OS -- 0.139
 
   5 year fair 
793 ELND 
Tsutsumida, 
2007
50
 
Retrospective 
> 1.5 
mm 
30 SLN 
DFS 
87.2% 
0.280 
   3 year fair 
72 ELND 72.7%  
12 + SLN 82.5% 
0.90 
19 + ELND 72.2% 
Rutkowski, 
2003
39
 
Retrospective 
database 
review 
Stage 
III 
145 +SLN + 
CLND 
OS 
41% 
ns DFS 
35% 
ns 5 year fair 
205 DLND 42% 31% 
Morton, 
2003
47
 
Retrospective 
database 
review 
Stage 
I/II 
 
287 
SLN+CLND 
OS
§ 
73% / 
69%/ 69% 
< 
0.001 
 
5/10/15 
year 
fair 
287  DLND 
51% / 
37% / 
32% 
Kretschmer, 
2004
46
 
Retrospective 
database 
review 
Stage 
I/II 
314 
SLN+CLND OS 
62.5% 
0.002  5 year fair 
623 DLND 50.2% 
Van Akooi, 
2007
49
 
Retrospective 
database 
Stage 
I/II 
64 SLN + 
CLND OS 
13% 
difference 
0.1115  5 year fair 
124 DLND 
Starz, 2004
48
 
Retrospective 
database 
review 
Breslow 
> 
0.75mm 
324 SLN  
CLND 
OS 
 
~ 65% 
0.03 
RFS 
(distant 
mets) 
 
~ 75% 
0.006 
8 year fair 274 WLE  
DLND 
~ 30% ~ 35% 
70 + SLN  ~ 65% 0.0419 ~75% 0.0048 
 54 
CLND 
57 + DLND 
~ 35% 
 
~ 38% 
Morton, 
2006
38
 
RCT 
1.2-3.5 
mm 
814 SLN  
CLND 
DFS 
78.31.6% 
0.009 
Melanoma 
specific 
survival 
87.11.3% 
0.58 
5 year  fair 
533 WLE  
DLND 
73.12.1% 87.11.3% 
SLN+CLND 
  
72.34.6% 
0.004 
WLE+DLND 52.45.9% 
Möhrle, 
200452 
Observational 
cohort 
Stage 
I/II 
271 +/-SLN RR of 
melanoma-
related 
death 
0.8 0.37 
 fair 
2,617 observe 
238 - SLN 
RR 0.75 0.36 
2,617 observe 
33 + SLN 
RR 0.73 0.38 
246 observe 
Gutzmer, 
2005
44
 
Retrospective 
database 
review 
Stage 
I/II 
296 SLN 
OS -- 0.32 RFS 
~ 78%  
0.0064 4 year poor 
377 no SLN  ~ 65%  
Koskivuo, 
2007
45
 
Retrospective 
case-control 
cohort 
Stage 
I/II 
305 SLN  
OS 
87.8% 
0.66 DFS 
85.1% 
0.42 
5 year fair 
616 control 82.5% 79.0% 
+ SLN ~ 76%  < 
0.001 
   
control ~ 82% 
Starz, 2007
40
 retrospective 
Breslow 
0.76-
1mm 
87 WLE + SLN 
OS  0.99 
Melanoma 
specific 
survival  
0.03 
 fair 
61 WLE  RFS 0.01 
 55 
*The 267 patients were matched based on gender, age, site of primary tumor, and the breslow thickness.  
+ The difference in follow-up times for the two groups was statistically significant (p=0.001) but was controlled for via statistical methods. 
∫  There was no sig difference b/w ELND and SLN/CLND for patients that were node positive.  
£ Nonsignificant trend favoring of SLN/CLND  
€ This shows subgroup analysis of patients w/ breslow thickness >1mm only. All patients with positive nodal disease were excluded from analysis.  
§  Analysis is based on 287 pairs matched on pT stage, ulceration, age, sex, and total number of involved nodes.  
 
 
